Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease.
Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease.
复制标题
DOI：
10.1016/j.ijrobp.2020.12.003
复制
发表时间：
2021-03-15
期刊：
影响因子：
--
通讯作者：
Chalmers AJ
中科院分区：
文献类型：
--
作者：
Hanna CR;Robb KA;Blyth KG;Jones RJ;Chalmers AJ
目前对2019冠状病毒病（COVID-19）肺部疾病的治疗效果有限。低剂量放射治疗（LDRT）作为一种潜在的治疗这种疾病的方法受到了关注和批评。在这项定性研究中，我们探讨了临床医生的观点，以确定在临床试验中测试LDRT和在临床实践中实施LDRT的障碍。半结构化访谈进行了6名临床医生从3个医学学科。访谈记录，逐字转录，并分析了主题，使用框架的方法。从数据中确定了关于使用LDRT治疗COVID-19肺病的障碍的共同主题。出现了三类障碍：（1）对患者造成伤害的可能性，包括难以预测伤害和缺乏现有数据来量化风险;（2）在临床环境中试验这种新型治疗策略的可行性，特别是试验设计和招募、患者选择和相关临床医生群体的认可;以及（3）提供治疗的后勤，特别是传播给其他患者的风险和患者转移所需的资源。本研究从3个相关专业的临床医生的角度确定了可能阻碍LDRT作为COVID-19肺部疾病治疗的评估和后续实施的几个障碍。通过记录和阐述这些问题，我们希望加强对这些障碍存在原因的讨论，并使其能够以积极的方式得到解决，以促进对COVID-19肺病患者放射治疗潜在益处的研究。
Current treatments for coronavirus disease 2019 (COVID-19) lung disease have limited efficacy. Low-dose radiation therapy (LDRT) has received both interest and criticism as a potential treatment for this condition. In this qualitative study we explored clinicians’ perspectives to identify barriers to testing LDRT in clinical trials and implementing it in clinical practice. Semistructured interviews were undertaken with 6 clinicians from 3 medical disciplines. Interviews were recorded, transcribed verbatim, and analyzed thematically, using a framework approach. Common themes regarding barriers to using LDRT for COVID-19 lung disease were identified from the data. Three categories of barriers emerged: (1) the potential to do harm to the patient, including difficulty in predicting harm and lack of existing data to inform quantification of risks; (2) the feasibility of trialing this novel treatment strategy in the clinical setting, in particular trial design and recruitment, patient selection and buy-in from relevant clinician groups; and (3) the logistics of delivering the treatment, in particular risks of transmission to other patients and resources required for patient transfer. This study identified several barriers that may impede the evaluation and subsequent implementation of LDRT as a treatment for COVID-19 lung disease, from the perspectives of clinicians in 3 relevant specialties. By documenting and articulating these concerns, we hope to enhance discussion of why these barriers exist, and enable them to be addressed in a proactive manner to facilitate research into the potential benefits of radiation treatment for patients with COVID-19 lung disease going forward.
登录
查看更多内容
DOI：
10.1016/j.ijrobp.2020.07.026
发表时间：
2020-12-01
影响因子：
7
作者：
Ameri, Ahmad;Rahnama, Nazanin;Taghizadeh-Hesary, Farzad
通讯作者：
Taghizadeh-Hesary, Farzad
Covid-19-19肺炎的低剂量全肺辐射：计划的第7天进行了注册临床试验的临时分析。
影响因子：
6.2
作者：
Hess CB;Buchwald ZS;Stokes W;Nasti TH;Switchenko JM;Weinberg BD;Steinberg JP;Godette KD;Murphy D;Ahmed R;Curran WJ Jr;Khan MK
通讯作者：
Khan MK
DOI：
10.1080/2159676x.2019.1704846
发表时间：
2019-12-27
影响因子：
4.9
作者：
Braun, Virginia;Clarke, Victoria
通讯作者：
Clarke, Victoria
影响因子：
158.5
作者：
Horby, Peter;Lim, Wei Shen;Landray, Martin J.
通讯作者：
Landray, Martin J.
影响因子：
105.7
作者：
Mays, N;Pope, C
通讯作者：
Pope, C